创新药的“含金量”还在提升！恒瑞医药出海放大招，创新药ETF(159992)涨超3%

Group 1 - The market showed signs of recovery with the ChiNext index leading gains, driven by active capital and strong performance in the pharmaceutical sector, particularly in innovative drug stocks [1] - Heng Rui Medicine announced a licensing agreement with Merck for its oral small molecule inhibitor HRS-5346, which expands its international market presence and accelerates global R&D, enhancing confidence in the innovative drug sector [1] - China Galaxy noted that the pharmaceutical sector has experienced a long adjustment period, resulting in low overall valuations and public fund underweighting, but anticipates a recovery in the pharmaceutical market driven by policy support [2] Group 2 - The innovative drug industry and medical device exports are expected to benefit from policy support and growing market demand, with leading companies in niche sectors likely to stand out [2] - The recovery of pharmaceutical consumption is anticipated to gradually manifest with economic recovery and consumption upgrades [2] - Overall, the pharmaceutical sector presents structural opportunities that warrant close attention [2]